Wrap Text
ASPI announces Paul Mann to return from temporary leave of absence as executive chairman and chief executive officer
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
ASPI ANNOUNCES PAUL MANN TO RETURN FROM TEMPORARY LEAVE OF ABSENCE AS
EXECUTIVE CHAIRMAN AND CHIEF EXECUTIVE OFFICER
Washington, D.C., December 2, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI
("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of
technology and processes for the production of isotopes for use in multiple industries, today announced
that, effective January 19, 2026, Paul Mann, the founder and Executive Chairman of ASP Isotopes, will
resume his role as the Company's Chief Executive Officer and continue as Executive Chairman.
On September 29, 2025, it was announced that Mr. Mann would be taking a temporary leave of absence
from his Chief Executive Officer duties for health reasons, and that the Company's Board of Directors
had appointed Robert Ainscow, the Company's Chief Operating Officer, to serve as Interim Chief
Executive Officer, in addition to his current duties. Mr. Mann is now able to travel again and he will
resume full day-to-day CEO duties as of January 19, 2026.
Robert Ainscow, who assumed Mr. Mann's CEO duties during his leave of absence, will continue in his
position as Chief Operating Officer. Mr. Mann is grateful to Mr. Ainscow for leading in an expanded role
and commented:
"I would like to take this opportunity to thank the executive management team of ASP Isotopes for
continuing to run the Company whilst I was recovering. I'm pleased to be returning as CEO at an
important moment for the Company. Over recent weeks, I've had detailed and constructive discussions
with a broad group of shareholders, and their perspectives have been carefully reflected in our plans.
As founder and largest shareholder, my focus is firmly aligned with long-term value creation. We have
strengthened our execution frameworks and now have greater clarity and confidence as we move
forward. With strong foundations in place, we believe 2026 has the potential to be a highly
transformative year for the Company."
About ASP Isotopes Inc.
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development
of technology and processes to produce isotopes for use in multiple industries. The Company employs
proprietary technology, the Aerodynamic Separation Process ("ASP technology"). The Company's initial
focus is on producing and commercializing highly enriched isotopes for the healthcare and technology
industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum
Enrichment technology that the Company is developing. The Company has isotope enrichment facilities
in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass
(light isotopes).
There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and
Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging
healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy
applications. We believe the ASP technology (Aerodynamic Separation Process) is ideal for enriching
low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are
neither historical facts nor assurances of future performance. Instead, they are based only on our
current beliefs, expectations, and assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and trends, the economy, and other future conditions.
Forward-looking statements can be identified by words such as "believes," "plans," "anticipates,"
"expects," "estimates," "projects," "will," "may," "might," and words of a similar nature. Examples of
forward-looking statements include, among others but are not limited to, the future of the company's
enrichment technologies as applied to uranium enrichment, the outcome of the company's initiative to
commence enrichment of uranium in South Africa and the company's discussions with nuclear
regulators, the outcome of the project contemplated with Necsa, the expected need or desire for HALEU
by third parties, the outcome of the transactions contemplated by the definitive agreements with
TerraPower, potential receipt of additional funding and effects, the commencement of supply of isotopes
to customers, the construction of additional enrichment facilities, and statements we make regarding
expected operating results, such as future revenues and prospects from the potential commercialization
of isotopes, future performance under contracts, and our strategies for product development, engaging
with potential customers, market position, and financial results. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that
are difficult to predict, many of which are outside our control. Our actual results, financial condition, and
events may differ materially from those indicated in the forward-looking statements based upon a
number of factors. Forward-looking statements are not a guarantee of future performance or
developments. You are strongly cautioned that reliance on any forward-looking statements involves
known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-
looking statements. There are many important factors that could cause our actual results and financial
condition to differ materially from those indicated in the forward-looking statements, including, but not
limited to: the failure to obtain necessary regulatory and shareholder approvals for the proposed
acquisition of Renergen; disruption from the proposed acquisition of Renergen making it more difficult
to maintain business and operational relationships; significant transaction costs and unknown liabilities
related to the proposed acquisition of Renergen; litigation or regulatory actions related to the proposed
acquisition of Renergen; the outcomes of various strategies and projects undertaken by the Company;
the potential impact of laws or government regulations or policies in South Africa, the United Kingdom
or elsewhere; our reliance on the efforts of third parties; our future capital requirements and sources
and uses of cash; our ability to obtain funding for our operations and future growth; our reliance on the
efforts of third parties; our ability to complete the construction and commissioning of our enrichment
plants or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process;
our ability to obtain regulatory approvals for the production and distribution of isotopes; the financial
terms of any current and future commercial arrangements; our ability to complete certain transactions
and realize anticipated benefits from acquisitions and contracts; dependence on our Intellectual
Property (IP) rights, certain IP rights of third parties; the competitive nature of our industry; and the
factors disclosed in Part I, Item 1A. "Risk Factors" of the company's Annual Report on Form 10-K for
the fiscal year ended December 31, 2024 and any amendments thereto and in the company's
subsequent reports and filings with the U.S. Securities and Exchange Commission. Any forward-looking
statement made by us in this press release is based only on information currently available to us and
speaks only as of the date on which it is made. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information, future developments or otherwise.
All forward-looking statements herein are qualified by reference to the cautionary statements set forth
herein and should not be relied upon.
Contacts
Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
The Company has a primary listing on the Nasdaq and a secondary listing on the Main Board of the
JSE.
2 December 2025
Sponsor
Valeo Capital Proprietary Limited
Date: 02-12-2025 04:20:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
